Rani Therapeutics Holdings (RANI) Enterprise Value (2020 - 2026)

Rani Therapeutics Holdings' Enterprise Value history runs 7 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 79.8% year-over-year to -$2.5 million in Q1 2026; TTM through Mar 2026 was -$2.5 million, a 79.8% increase from a year earlier, with the FY2025 full-year figure at -$10.1 million, down 347.41% from the prior year.
• Enterprise Value rose to -$2.5 million in Q1 2026 per RANI's latest filing, from -$10.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at $57.3 million in Q1 2022 and bottomed at -$88.4 million in Q4 2022.
• The 5-year median for Enterprise Value is -$1.6 million (2024), against an average of $1.9 million.
• Across the five-year window, Enterprise Value soared 173.35% in 2022 and tumbled 4870.77% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$88.4 million in 2022, then surged by 107.6% to $6.7 million in 2023, then slumped by 133.68% to -$2.3 million in 2024, then slumped by 347.41% to -$10.1 million in 2025, then soared by 75.23% to -$2.5 million in 2026.
• Per Business Quant, the three latest RANI Enterprise Value figures stand at -$2.5 million (Q1 2026), -$10.1 million (Q4 2025), and -$8.3 million (Q3 2025).